Cancer cachexia is a wasting syndrome characterized by weight loss, anorexia, asthenia and anemia. The pathogenicity of this syndrome is a result multiple factors, due to a complex interaction of tumor and host factors. It is generally related with chronic inflammatory conditions and cancer. Cachexia is a serious condition as it consumes other sources of energy, like skeletal muscle and adipose tissue when the body senses a lack of nutrition. It adversely affects the patients’ ability to fight against infection and withstand ongoing treatments such as chemotherapy and radiotherapy. As a result of these negative effects, the body begins to waste away leading to death. Clinical trials in progress in oncology field have highlighted the multifactorial pathogenicity of cachexia. Understanding the mechanism of cancer cachexia has become crucial for the understanding of prognostic factors for cancer. Cachexia is often a permanent side effect of diseases like HIV and Cancer. Biologics and pharmaceutical organizations are adopting practices that ensure the availability of the product in the market at a rapid pace. This strategic approach is helping them bolster their position in the global cancer cachexia market.
COVID – 19 scenario analysis:
- Due to the COVID – 19 outbreak, majority of healthcare, pharmaceutical and biotechnology organizations have concentrated on diagnostics kits, safety wearables (PPE kits, face shields, masks) and treatment therapies and medication against Novel coronavirus
- R&D labs are also focusing on finding a breakthrough vaccine against novel coronavirus
- In addition, the medical professionals are engaged in providing COVID-19 related services, as a result, other healthcare segments have to face negligence
- As there is strain on healthcare providers and the hospitals are flooding with patients suffering with novel coronavirus and the intake capacity of hospitals already at its peak, the cancer cachexia patients and their treatments have been either postponed or put on hold as the health professionals are summoned to fight COVID-19
- Some research from China, has also stated that cancer patients are at higher risk as they’re vulnerable against novel coronavirus and have higher chances of getting infected with the virus
Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis
Factors like increasing prevalence of cancer and cancer cachexia in patients, the demand for therapeutic treatment and drugs have increased all over. This rising demand for therapeutics in the market has accelerated the R&D activities in order to develop novel therapeutic drugs. This has led to creation of a strong product pipeline consisting various therapy products. These factors have been major reason for the growth of the market. In addition, increased awareness has regarding this syndrome and advancements related to treatment of cancer cachexia has also helped the market growth. Randomized trials have highlighted the growing potential of new chemotherapy agents. The use of combination chemotherapy in the adjuvant setting to improve survival rates has been positive. The cancer cachexia market will gather significant pace due to growing awareness about improving the quality of life for cancer patients. Researchers are experimenting in the search of specific drugs to cure this syndrome using pharmacological treatments with diverse chemical compounds. The non-steroidal anti-inflammatory drugs (NSAIDs) have shown promising results in this scenario.
On the contrary, lack of studies and research that could explain high efficacy of a specific treatment, making the progress in the cancer cachexia market has been considerably at slower pace. The manufacturers of cancer cachexia drugs are hesitant while investing in the market because of the stringent regulatory guideline which may restrict the long-term growth of this market.
Use of multidisciplinary approach and development of combined therapies to surge the market growth
According to National Center for Biotechnology Information (NCBI), it is estimated that half of all patients suffering with cancer will develop cancer cachexia, leading to progressive loss of adipose tissue and skeletal muscle mass. Cachexia syndrome has dramatic impacts on patient quality of life along with poor responses to treatments like chemotherapy and decreased survival chances. But still, cachexia is underestimated and untreated condition, despite numerous mechanisms reported to be engaged in its development. Therapies for treatment of cachexia include or exigenic appetite stimulants, focus on palliation of symptoms and reduction of the distress of patients. The past therapies haven’t been much effective as they were targeting a single aspect of this syndrome while multi-faceted approach was needed. Recent developments in therapies for cancer cachexia feature multiple integrated approaches. For instance, combination therapy supplemented with diet modification and exercise routine has been an addition conventional to novel pharmaceutical agents, such as Megestrol, medroxyprogesterone, ghrelin, omega-3-fatty acid among others. The use of these agents along with diet and exercise regime reported to have improved survival rates as well as quality of life for the patient. These advancements would prove to be a boon for patients struggling with cancer cachexia syndrome and boost the growth of the cancer cachexia market in the years to come.
North American region expected to dominate the Cancer Cachexia Market
The U.S. alone accounted for an estimated 1.8 million cancer patients and over 606,000 deaths in 2019 and this number is expected to grow with time. American region is expected to grow due to factors like rising incidence of cancer patients and hence cancer cachexia as well with the presence of large number of drug manufacturers and key players in the market along with advancing paradigm of care for cancer patients that is supporting the growth in this region. As a result, this segment holds the largest market share. Furthermore, factors such as a rising number of geriatric population along with an increasing healthcare spending in the region and the availability of advanced healthcare infrastructure would to stimulate the market growth in this region.
Key benefits of the report:
- This study presents the analytical depiction of the global cancer cachexia industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global market share.
- The current market is quantitatively analysed to highlight the global cancer cachexia market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed global market analysis based on competitive intensity and how the competition will take shape in coming years.
Questions answered in the Cancer Cachexia Market research report:
- Who are the leading market players active in the cancer cachexia market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities in the market?
- What are the projections for the future that will help in taking further strategic steps?
Cancer Cachexia Market, by Drugs Report Highlights
| Aspects | Details |
 By Drugs |
|
 By Mode of action |
|
 By Distribution channels |
|
 By Region |
|
 Key Market Players | Merck & Co. Inc., GTx Inc., Pernix Therapeutics, Eli Lilly and Company, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company., Eterna Zentaris, XBiotech, Inc., Alder BioPharmaceuticals Inc., SkyePharma, Pfizer Inc, Sanofi, Novartis AG, Purdue Pharma L.P. |
Loading Table Of Content...
